[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100496314":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":30,"responsibleParty":32,"collaborators":30,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":30,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":30,"overallStatus":54,"whyStopped":30,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":30},{"fullName":5,"class":6},"Xijing Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"anlotinib+CAPEOX\u002FSOX","EXPERIMENTAL","Adjuvant treatment of locally advanced gastric cancer and colorectal cancer",[13],"Drug: anlotinib+CAPEOX\u002FSOX",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients with colorectal cancer use the anlotinib+CAPEOX protocol, and patients with gastric cancer use the anlotinib+SOX protocol.\n\nAnlotinib: 12mg, administered once a day on day 1-14, taken about half an hour before breakfast (the time of daily administration should be the same as much as possible), delivered with warm water, repeated once every three weeks;\n\nCAPEOX: capecitabine 1000mg\u002Fm2 each time, oral, twice a day, 1-14 days; Oxaliplatin: 130mg\u002Fm2 iv drip d1.\n\nSOX: Tegio: 100mg\u002Fday, continuous medication for 2 weeks, stop for 1 week; Oxaliplatin: 130mg\u002Fm2 iv drip d1.",[9],[20],"anlotinib+chemotherapy",[22],{"name":23,"affiliation":24,"role":25},"DeLiang Yu, Doctor","Ambulatory Surgery Center","STUDY_CHAIR",[27],{"name":23,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","0086-15339290897",null,"ydl0915@163.com",{"type":33,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100496314","adjuvant-treatment-of-digestive-tract-tumors-100496314",false,"NCT05742620","Adjuvant Treatment of Digestive Tract Tumors","Follow-up and Registration Study of Anlotinib Combined With Adjuvant Chemotherapy in the Treatment of Locally Advanced Gastrointestinal Tumors","ATDTT","Inclusion Criteria:\n\n* 1.18 years old ≤ age ≤ 75 years old, male or female;\n* 2\\. ECOG score 0\\~2 points;\n* 3\\. Patients with locally advanced gastric cancer and colorectal cancer after radical surgery (R0 resection);\n* 4\\. Gastric cancer: patients with stage III (pT1N3bM0, pT2N3M0, pT3N2-3M0, pT4aN1-3M0, pT4bN0-3M0);\n* 5\\. Colorectal cancer: patients with stage III (T any N+M0);\n* 6\\. Normal function of main organs\n* 7\\. Female subjects of childbearing age must carry out a serum pregnancy test within 3 days before starting the study medication, and the result is negative, and are willing to use a medically approved effective contraceptive measure (such as intrauterine device, contraceptive or condom) during the study period and within 3 months after the last administration of the study medication; For male subjects whose partners are women of childbearing age, they should undergo surgical sterilization or agree to use effective methods of contraception during the study and within 3 months after the last study administration.\n* 8\\. Subjects voluntarily joined the study and signed the informed consent form, with good compliance and cooperation in follow-up.\n\nExclusion Criteria:\n\n* 1\\. Postoperative distal metastasis or failure to achieve R0 resection;\n* 2\\. Have experienced any anti-tumor treatment before surgery, including chemotherapy, radiotherapy and targeted drug treatment;\n* 3\\. Patients with contraindications to chemotherapy;\n* 4\\. Other malignant tumors in the past 3 years;\n* 5\\. Clinically obvious bleeding symptoms or obvious bleeding tendency (such as gastrointestinal bleeding, gastric ulcer bleeding, gastrointestinal bleeding, hemorrhagic gastric ulcer, stool occult blood++or above the baseline, or vasculitis);\n* 6\\. Uncontrolled hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, despite the best drug treatment);\n* 7\\. People newly diagnosed with angina pectoris within 3 months before screening or suffering from serious cardiovascular diseases within 6 months before screening, including unstable angina pectoris or myocardial infarction; Arrhythmias (including QTcF: male ≥ 450 ms, female ≥ 470 ms) require long-term use of antiarrhythmic drugs; ≥ Grade 2 congestive heart failure (NYHA classification);\n* 8\\. Severe infection (such as the need for intravenous drip of antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first administration, or fever of unknown cause occurred during screening\u002Fbefore the first administration\\>38.5 ° C;\n* 9\\. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* 10\\. Pregnant or lactating women; Those with fertility who are unwilling or unable to take effective contraceptive measures;\n* 11\\. It is known that it will produce allergy, hypersensitivity or intolerance to the test drug and its excipients;\n* 12\\. Subjects who are participating in other clinical studies or whose first medication is less than 4 weeks from the end of the previous clinical study (the last medication), or who have 5 half-lives of the study drug;\n* 13\\. Subjects are known to have a history of abuse of psychotropic substances, alcohol or drug abuse;\n* 14\\. The researcher believes that there are any conditions that may harm the subject or cause the subject to fail to meet or perform the research requirements.","ALL","18 Years","75 Years",{"count":46,"type":47},100,"ESTIMATED","INTERVENTIONAL",[50],"NA","To evaluate the 3-year Disease-free survival rate(DFSR) of patients with locally advanced gastric cancer and colorectal cancer treated with anlotinib combined with adjuvant chemotherapy.",[53],"Adjuvant Treatment","NOT_YET_RECRUITING","2023-02-15",{"date":57,"type":58},"2023-02-24","ACTUAL",{"date":60,"type":47},"2023-06-20",{"date":62,"type":47},"2029-07-20",{"name":5,"class":6}]